Actinogen Medical
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 9 Oct 2026
- Reported shorts
- 15.9K
- Shares on issue
- 3.874B
Actinogen Medical (ACW) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $499.9KM (source: ASX (Markit))vs $685.3KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$15.4Mvs −$14.7M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.005vs −$0.005 (FY25)
- Yahoo Finance, as at 14 Oct 2026
- Rev YoY
- −27.1%FY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of ACW Appendix 4E and 2026 annual report, 27 Aug 2026
Actinogen Medical reported revenue of $0.5M for FY2026, down 27% from the prior year, and a net loss of $15.4M (up 4.4% from $14.7M). No dividend was declared. The company expects topline results from its pivotal XanaMIA Alzheimer's trial in November 2026, with cash runway to mid-2027.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −5,624.3%
- Net margin
- −3,076.8%
- FCF margin
- −3,514.8%
- ROE
- −77.5%
- ROA
- −56.9%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $12.1M
- Net debt / EBITDA
- n/a
- Current ratio
- 3.4×
- Interest cover
- −60.3×
- Cash dividends paid / net profit
- n/a
- Market cap
- $171.0M
- P/E
- n/a
- P/B
- 8.0×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $499.9KM (source: ASX (Markit)) | $685.3KM (source: ASX (Markit)) | $291.0KM (source: ASX (Markit)) | $366.6KM (source: ASX (Markit)) |
| Operating income | −$28.1M | −$20.8M | −$23.2M | −$15.9M |
| EBITDA | −$14.5M | −$14.3M | −$12.6M | −$10.3M |
| EBIT | −$14.9M | −$14.7M | −$13.0M | −$10.7M |
| Interest expense | $465.9K | $48.9K | $24.3K | $16.6K |
| Pretax income | −$15.4M | −$14.7M | −$13.0M | −$10.8M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$15.4M | −$14.7M | −$13.0M | −$10.8M |
| Net interest income | $33.9K | $636.4K | $266.7K | $350.1K |
| EPS basic | −$0.005 | −$0.005 | −$0.006 | −$0.006 |
| EPS diluted | −$0.005 | −$0.005 | −$0.006 | −$0.006 |
| Shares | 3.72B | 3.18B | 2.68B | 1.92B |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- ACW Appendix 4E and 2026 annual reportAnnual Results27 Aug 2026via asx_announcements
- June 2026 Quarterly activity report & Appendix 4CQuarterly Report30 Jul 2026via asx_announcements
- ACW December 2025 quarterly activity report & Appendix 4CQuarterly Report29 Apr 2026via asx_announcements
- Correction-March2026 quarterly activity report & Appendix 4CQuarterly Report29 Apr 2026via asx_announcements
- Actinogen HY2025 financial report and Appendix 4DHalf Year Results26 Feb 2026via asx_announcements
- ACW December 2025 quarterly activity report & Appendix 4CQuarterly Report30 Jan 2026via asx_announcements
- ACW September 2025 quarterly activity report & Appendix 4CQuarterly Report23 Oct 2025via asx_announcements
- Annual Report to ShareholdersAnnual Report15 Oct 2025via asx_announcements
- ACW Appendix 4E and 2025 annual reportAnnual Results25 Aug 2025via asx_announcements
- Actinogen June 2025 quarterly activity report & Appendix 4CQuarterly Report30 Jul 2025via asx_announcements
Showing 10 of 94 reports